Share
FacebookTwitterLinkedinReddItEmailAngela M. Cacace, PhD
Chief Scientific Officer
Arvinas
Panelist
Angela M. Cacace, PhD
Dr. Angela Cacace serves as Chief Scientific Officer (CSO) at Arvinas. Prior to her role as CSO, Dr. Cacace most recently served as Senior Vice President, Neuroscience and Platform Biology. Dr. Cacace has three decades of drug discovery experience in neuroscience and oncology research across modalities. During her time at Arvinas, Dr. Cacace has led the continuous evolution of our PROTAC Discovery Engine to employ new E3 ligases and cross the blood-brain barrier for multiple neurologic disease targets.
Previously, Dr. Cacace served as the Vice President of Biology at Fulcrum Therapeutics, where she built the biology platform, grew talented scientific teams, delivered the first development candidates, and guided the development of translational biomarkers to enable clinical development programs.
Additionally, Dr. Cacace served in positions of increasing responsibility at Bristol Myers Squibb, including as the Director of Neuroscience and Genetically Defined Diseases, where she spearheaded alternative therapeutic modalities and was a co-inventor on several development candidates. Throughout her time at Bristol Myers Squibb, she was responsible for building research-wide teams and initiatives, including the Lead Discovery and Optimization functions. While serving as a Sr. Principal Scientist in Cancer Biology at Pfizer, together with her team, she discovered a novel anti-angiogenic antibody development candidate. Dr. Cacace currently serves on the Board of Directors for BioCT.
Dr. Cacace received her B.S. in Biology from Fairfield University, Ph.D. in Pharmacology from Columbia University and completed her postdoctoral research in Oncology at Bristol Myers Squibb and the National Cancer Institute.
Broadcast Date:Thursday, October 1, 2026
- Time:08:00 PDT, 11:00 EDT, 17:00 CET
Neurodegenerative diseases such as Alzheimer’s and Parkinson’s remain some of the most challenging conditions to treat. Despite decades of research, small molecule inhibitors have shown limited clinical benefit for treating misfolded proteins, while amyloid-beta-focused approaches have been shown to address only one of many underlying disease drivers. Repeated late-stage failures have underscored the biological complexity of these disorders.
Targeted protein degradation is emerging as a promising modality for eliminating disease-driving proteins. By selectively reducing pathogenic protein levels, degraders may offer a way to address neurodegenerative and neuromuscular diseases by targeting proteins that lack conventional druggable sites.
In thisGENwebinar, our expert speaker will discuss the increasing rationale for targeting key drivers of neurological disease with protein degraders and how this approach may enable deeper, more precise modulation of disease biology. Key takeaways from the webinar will include:
- Targeted protein degradation could help address the underlying biology of neurodegenerative and neuromuscular diseases.
- Protein degraders are designed to selectively eliminate disease-driving proteins that have historically been difficult or impossible to target, potentially expanding the range of tractable targets in neurology.
- In preclinical experiments, certain protein degraders have shown the ability to reach the target in the brain or muscle, reduce the disease-associated protein, and affect downstream biological pathways.
A live Q&A session will follow the presentation offering you a chance to pose questions to our expert speaker.
Produced with support from:
